tiprankstipranks
Senzime AB (SNZZF)
OTHER OTC:SNZZF

Senzime AB (SNZZF) Price & Analysis

2 Followers

SNZZF Stock Chart & Stats

$0.54
<$0.01(0.02%)
At close: 4:00 PM EST
$0.54
<$0.01(0.02%)

Bulls Say, Bears Say

Bulls Say
Recurring Revenue From SensorsSensors drive a razor‑and‑blades recurring revenue stream that accounted for the majority of sales growth. A growing installed base and 1M monitored‑patient milestone increase predictability and gross‑margin leverage, supporting durable cash generation as consumable volumes scale.
Installed Base ExpansionA broad and expanding installed base creates a long‑term demand floor for consumables and services. Each new monitor increases recurring sensor consumption and cross‑sell opportunities, improving lifetime customer value and making revenue less dependent on one‑time capital sales.
Platform Integrations And New Service ModelsEHR integrations and partner OEM relationships deepen product stickiness and open recurring service monetization. The As‑a‑Service model shortens sales cycles for some customers and enhances recurring revenue mix, supporting sustainable margin expansion and adoption.
Bears Say
High Operating Cash BurnSustained negative operating and free cash flow necessitate funding or draw on balance sheet resources. Until operations achieve consistent cash‑flow positivity, the company faces refinancing risk, constrained reinvestment capacity, and pressure to execute commercial milestones reliably.
Deep Negative Profitability And Revenue DecelerationSharp revenue deceleration combined with deeply negative operating and net margins indicate the business is not yet scaled to cover fixed costs. Persistent losses can erode equity, limit reinvestment, and make achieving sustainable profitability dependent on execution and margin improvements.
Hospital Purchasing And Regulatory Timing RiskDependence on slow hospital procurement, IDN approvals and regionally staggered regulatory clearances creates execution timing risk. Delays can defer revenue recognition and sensor consumption, making cash‑flow targets and margin improvements contingent on overcoming structural sales frictions.

Senzime AB News

SNZZF FAQ

What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was $0.43 and its highest was $0.79 in the past 12 months.
    What is Senzime AB’s market cap?
    Senzime AB’s market cap is $71.89M.
      When is Senzime AB’s upcoming earnings report date?
      Senzime AB’s upcoming earnings report date is Jul 16, 2026 which is in 31 days.
        How were Senzime AB’s earnings last quarter?
        Senzime AB released its earnings results on Apr 22, 2026. The company reported -$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.015.
          Is Senzime AB overvalued?
          According to Wall Street analysts Senzime AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Senzime AB pay dividends?
            Senzime AB does not currently pay dividends.
            What is Senzime AB’s EPS estimate?
            Senzime AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Senzime AB have?
            Senzime AB has 157,215,040 shares outstanding.
              What happened to Senzime AB’s price movement after its last earnings report?
              Senzime AB reported an EPS of -$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Senzime AB?
                Currently, no hedge funds are holding shares in SNZZF
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Senzime AB

                  Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.

                  Senzime AB (SNZZF) Earnings & Revenues

                  SNZZF Company Deck

                  SNZZF Earnings Call

                  Q4 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call conveyed a generally positive outlook: the company reported strong underlying operational momentum (notably sensor growth, a 1M monitored‑patient milestone, margin improvement, new business models like TetraGraph‑as‑a‑Service, TetraCom and important customer wins) while acknowledging a temporary Q1 growth dip driven by delayed U.S. deals, FX and tariff headwinds and some regional regulatory timing issues. Management emphasizes cost discipline, a solid pipeline, available funding and confidence in meeting full‑year objectives, but execution (recovering delayed deals, FX/tariff resolution and regulatory rollouts) is needed to realize targets.View all SNZZF earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bactiguard Holding AB
                  C-Rad AB Class B
                  Integrum AB Class B
                  Sedana Medical AB
                  OssDsign AB

                  Ownership Overview

                  0.07%99.89%
                  Insiders
                  ― Other Institutional Investors
                  99.89% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks